98%
921
2 minutes
20
Cancer immunotherapy has emerged as a novel clinical therapeutic option for a variety of solid tumors over the past decades. The application of immunotherapy in primary and metastatic brain tumors continues to grow despite limitations due to the physiological characteristics of the immune system within the central nervous system (CNS) and distinct pathological barriers of malignant brain tumors. The post-immunotherapy treatment imaging is more complex. In this review, we summarize the clinical application of immunotherapies in solid tumors beyond the CNS. We provide an overview of current immunotherapies used in brain tumors, including immune checkpoint inhibitors (ICIs), oncolytic viruses, vaccines, and CAR T-cell therapies. We focus on the imaging criteria for the assessment of treatment response to immunotherapy, and post-immunotherapy treatment imaging patterns. We discuss advanced imaging techniques in the evaluation of treatment response to immunotherapy in brain tumors. The imaging characteristics of immunotherapy treatment-related complications in CNS are described. Lastly, future imaging challenges in this field are explored.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634813 | PMC |
http://dx.doi.org/10.3389/fimmu.2024.1496627 | DOI Listing |
Biochem Genet
September 2025
Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Kocamustafapasa, 34098, Istanbul, Turkey.
Glioblastoma is the most aggressive and malignant tumor of the central nervous system. Current treatment options, including surgical excision, radiotherapy, and chemotherapy, have Limited efficacy, with a median survival rate of approximately 15 months. To develop novel therapeutics, it is crucial to understand the underlying molecular mechanisms driving glioblastoma.
View Article and Find Full Text PDFBMJ Health Care Inform
September 2025
Center for Sleep and Circadian Medicine, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China
Objectives: The objectives were to examine the associations between accelerometer-measured circadian rest-activity rhythm (CRAR), the most prominent circadian rhythm in humans and the risk of mortality from all-cause, cancer and cardiovascular disease (CVD) in patients with cancer.
Methods: 7456 cancer participants from the UK Biobank were included. All participants wore accelerometers from 2013 to 2015 and were followed up until 24 January 2024, with a median follow-up of 9.
Nucleic Acids Res
September 2025
State Key Laboratory of Vaccines for Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361102, Fujian, China.
The abnormal expansion of GGGGCC (G4C2) repeats in the noncoding region of the C9orf72 gene is a major genetic cause of two devastating neurodegenerative disorders, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These G4C2 repeats are known to form G-quadruplex (G4) structures, which are hypothesized to contribute to disease pathogenesis. Here, we demonstrated that four DNA G4C2 repeats can fold into two structurally distinct G4 conformations: a parallel and an antiparallel topology.
View Article and Find Full Text PDFStem Cell Reports
September 2025
Laboratory of Neural Stem Cells and Functional Neurogenetics, Farmington, CT 06030, USA; Departments of Neuroscience, Neurology, Genetics and Genome Sciences, UConn Health, Farmington, CT 06030, USA. Electronic address:
Intratumoral heterogeneity in glioblastoma is thought to underlie its remarkable ability to recur and resist therapies. Its origins, however, remain unknown. In this issue, Liu et al.
View Article and Find Full Text PDFNanoscale Horiz
September 2025
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and National Center for Nanoscience and Technology of China, Beijing 100190, China.
Central nervous system (CNS) diseases, including neurodegenerative diseases, stroke, brain tumors, and others, result in poor quality of life and can cause substantial disability. Not all CNS diseases are amenable to surgical approaches, so drug development is important for disease treatment. Unfortunately, there are few drugs currently available for CNS diseases.
View Article and Find Full Text PDF